Evidence Explorer · MS-N229 · Traditional Chinese medicinal diet · Supportive care · Appraised November 4, 2026
A short randomized trial reported less fatigue and higher hemoglobin after a traditional Astragalus–Angelica preparation in people with chemotherapy-associated anemia after colon-cancer surgery. The large short-term differences are promising but need blinded, independently replicated confirmation.
Evidence at a glance
Benefit signal: Positive 21-day fatigue and blood-count signal
Certainty: Low; single-center, short, apparently unblinded trial with 10 participants not completing
Risk context: Product standardization, herb–drug interactions and longer-term safety were not established
What was studied
Ninety-six adults were randomized 1:1 to usual postoperative chemotherapy care with or without the medicinal diet; 86 completed the 21-day assessment. The traditional preparation used five parts honey-treated Astragali Radix to one part wine-processed Angelicae Sinensis Radix, boiled in water.
At day 21, fatigue scores were 29.14 versus 44.02 (mean difference −14.88, 95% CI −16.38 to −13.38). Hemoglobin was 115.26 versus 106.52 g/L (difference 8.74, 95% CI 3.45–14.03). Red-cell and inflammatory-marker differences also favored the intervention.
What this evidence cannot establish
The article does not establish how much of the difference arose from the herbs, calories, expectancy, concurrent care or differential attrition. Durability and a clinically meaningful fatigue threshold were not independently confirmed.
Blood counts and inflammatory markers are intermediate outcomes. The trial did not test tumor response, recurrence or survival.
Practical safety context
Astragalus and Angelica products vary substantially. Immune, bleeding, blood-pressure, glucose and cytochrome-mediated interaction concerns should be reviewed with an oncology pharmacist.
Anemia during chemotherapy requires clinical evaluation; a botanical preparation must not substitute for investigation of bleeding, marrow suppression, nutritional deficiency or disease progression.
Questions for the care team
- Was the studied preparation chemically standardized and independently tested?
- Could Angelica or Astragalus interact with anticoagulants, immunotherapy or other cancer medicines?
- What is the cause and appropriate treatment of the anemia?
- How will fatigue and blood counts be monitored without delaying standard care?
Funding and conflicts
Supported by two Fujian University of Traditional Chinese Medicine nursing-discipline grants. The authors declared no conflicts of interest.
Sources
- Randomized trial (PMID 42937728)
Sources and publication status checked November 4, 2026. Last literature search: November 4, 2026; record appraisal: November 4, 2026.
For education, not personal medical advice. Research regimens are not personal prescriptions. Symptom, laboratory or biomarker changes do not establish tumor response, recurrence prevention or longer survival.
